Literature DB >> 20414109

Bone mass measurements in men and women with chronic kidney disease.

Sophie A Jamal1.   

Abstract

PURPOSE OF REVIEW: Fractures are common in patients with chronic kidney disease (CKD) and are associated with substantial morbidity and mortality. Bone mass measurements are commonly used to assess fracture risk in the general population, but the utility of these measurements in patients with CKD is unclear. RECENT
FINDINGS: This review will outline the epidemiology and etiology of fractures in patients with CKD. Also, we will summarize the published data that describe the association between bone mass measurements and fracture in patients with CKD.
SUMMARY: Patients with CKD suffer from fractures due to impairments in bone quantity, bone quality, and abnormalities of neuromuscular function. The complex etiology of fractures combined with the technical limitations of bone mineral density testing, both by dual energy X-ray absorptiometry and by peripheral quantitative computed tomography, limits the clinical utility of bone mass measurements for fracture prediction in CKD; this is particularly true among patients with stages 4 and 5 CKD. As such, clinicians should not routinely order bone mineral density testing in patients with CKD. Further research, to determine whether bone mineral density together with other noninvasive measures to assess bone strength can predict fracture, is needed.

Entities:  

Mesh:

Year:  2010        PMID: 20414109     DOI: 10.1097/MNH.0b013e328338f520

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  8 in total

1.  The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease.

Authors:  S A Jamal; S L West; T L Nickolas
Journal:  Osteoporos Int       Date:  2013-10-11       Impact factor: 4.507

2.  Bone fracture risk factors in prevalent hemodialysis patients.

Authors:  Patrícia João Matias; Ivo Laranjinha; Ana Azevedo; Ana Raimundo; David Navarro; Cristina Jorge; Inês Aires; Marco Mendes; Carina Ferreira; Tiago Amaral; Célia Gil; Aníbal Ferreira
Journal:  J Bone Miner Metab       Date:  2019-09-05       Impact factor: 2.626

3.  Evaluation of bone densitometry by dual-energy x-ray absorptiometry as a fracture prediction tool in women with chronic kidney disease.

Authors:  Valeria E Gómez-Islas; Kevin R García-Fong; Rosa E Aguilar-Fuentes; Salvador Hernández-Castellanos; Alfredo Pherez-Farah; Sofía A Méndez-Bribiesca; Juan M López-Navarro; Hillary K Osorio-Landa; Sergio L Carbajal-Morelos; Areli M Zúñiga-Guzmán; Iván Pérez-Díaz
Journal:  Bone Rep       Date:  2020-07-18

4.  Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

Authors:  Erica L Clinkenbeard; Megan L Noonan; Joseph C Thomas; Pu Ni; Julia M Hum; Mohammad Aref; Elizabeth A Swallow; Sharon M Moe; Matthew R Allen; Kenneth E White
Journal:  JCI Insight       Date:  2019-02-21

5.  Comparison of clinical, biochemical and histomorphometric analysis of bone biopsies in dialysis patients with and without fractures.

Authors:  Melissa F P Santos; Mariel J Hernández; Ivone B de Oliveira; Flávia R Siqueira; Wagner V Dominguez; Luciene M Dos Reis; Aluizio B Carvalho; Rosa M A Moysés; Vanda Jorgetti
Journal:  J Bone Miner Metab       Date:  2018-01-25       Impact factor: 2.626

6.  Predictors of the rate of BMD loss in older men: findings from the CHAMP study.

Authors:  K Bleicher; R G Cumming; V Naganathan; M J Seibel; F M Blyth; D G Le Couteur; D J Handelsman; H M Creasey; L M Waite
Journal:  Osteoporos Int       Date:  2012-12-05       Impact factor: 4.507

7.  Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF.

Authors:  Jonathan A Wheeler; Erica L Clinkenbeard
Journal:  Curr Mol Biol Rep       Date:  2019-01-25

8.  Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease: A population-based retrospective cohort study.

Authors:  Hon-Jhe Chen; Hao-Yu Yang; Kuang-Chieh Hsueh; Cheng-Che Shen; Ru-Yi Chen; Hsien-Chung Yu; Tzu-Lin Wang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.